Show simple item record

dc.contributor.authorRodgers, J
dc.contributor.authorFriede, T
dc.contributor.authorVonberg, FW
dc.contributor.authorConstantinescu, CS
dc.contributor.authorColes, A
dc.contributor.authorChataway, J
dc.contributor.authorDuddy, M
dc.contributor.authorEmsley, H
dc.contributor.authorFord, H
dc.contributor.authorFisniku, L
dc.contributor.authorGalea, I
dc.contributor.authorHarrower, T
dc.contributor.authorHobart, J
dc.contributor.authorHuseyin, H
dc.contributor.authorKipps, CM
dc.contributor.authorMarta, M
dc.contributor.authorMcDonnell, GV
dc.contributor.authorMcLean, B
dc.contributor.authorPearson, OR
dc.contributor.authorRog, D
dc.contributor.authorSchmierer, K
dc.contributor.authorSharrack, B
dc.contributor.authorStraukiene, A
dc.contributor.authorWilson, HC
dc.contributor.authorFord, DV
dc.contributor.authorMiddleton, RM
dc.contributor.authorNicholas, R
dc.date.accessioned2022-03-04T10:35:56Z
dc.date.issued2021-10-08
dc.identifier.issn0006-8950
dc.identifier.issn1460-2156
dc.identifier.urihttp://hdl.handle.net/10026.1/18884
dc.description.abstract

<jats:title>Abstract</jats:title> <jats:p>The negative impact of smoking in MS is well established, however, there is much less evidence as to whether smoking cessation is beneficial to progression in MS.</jats:p> <jats:p>Adults with MS registered on the United Kingdom MS Register (2011-2020) formed this retrospective and prospective cohort study. Primary outcomes were changes in 3 patient reported outcomes (PROs): normalised MS Physical Impact Scale (MSIS-29-Phys), normalised MS Walking Scale (MSWS-12) and the Hospital Anxiety and Depression Scale (HADS-Anxiety and HADS-Depression). Time to event outcomes were clinically significant increases in the PROs.</jats:p> <jats:p>7983 participants were included, 4130 (51.7%) of these had ever smoked; of whom 1315 (16.5%) were current smokers and 2815/4130 (68.2%) were former smokers. For all PROs, current smokers at the time of completing their first questionnaire had higher PRO scores indicating higher disability compared to those who had never smoked (∼10 points difference in MSIS-29-Phys and MSWS-12; 1.5-1.8 point for HADS-anxiety and HADS-depression). There was no improvement in PRO scores with increasing time since quitting in former smokers.</jats:p> <jats:p>923 participants formed the prospective parallel group, which demonstrated that MSIS-29-phy 5.03, [3.71, 6.34], MSWS-12 5.28, [3.62, 6.94] and HADS-depression 0.71, [0.47, 0.96] worsened over a period of 4 years, whereas HADS-anxiety remained stable. Smoking status was significant at year 4; current smokers had higher MSIS-29-Phys and HADS-Anxiety scores (3.05 [0.22, 5.88], 1.14 [0.52,1.76]) while former smokers had a lower MSIS-29 score of -2.91[-5.03, -0.79].</jats:p> <jats:p>4642 participants comprised the time to event analysis. Still smoking was associated with a shorter time to worsening event in all PROs (MSIS-29-Phys: n = 4436, p = 0.0013; MSWS-12: n = 3902, p = 0.0061; HADS-anxiety: n = 4511, p = 0.0017; HADS-depression: n = 4511, p &amp;lt; 0.0001). Worsening in motor disability (MSIS-29-Phys and MSWS-12) was independent of baseline HADS-anxiety and HADS-depression scores. There was no statistically significant difference in the rate of worsening between never and former smokers.</jats:p> <jats:p>When smokers quit, there is a slowing in the rate of motor disability deterioration so that it matches the rate of motor decline in those who have never smoked. This suggests that smoking cessation is beneficial for people with MS.</jats:p>

dc.format.extent1368-1378
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherOxford University Press (OUP)
dc.subjectmultiple sclerosis
dc.subjectpublic health
dc.subjectepidemiology
dc.titleThe impact of smoking cessation on multiple sclerosis disease progression
dc.typejournal-article
dc.typeJournal Article
dc.typeResearch Support, Non-U.S. Gov't
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000784739900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue4
plymouth.volume145
plymouth.publication-statusPublished
plymouth.journalBrain
dc.identifier.doi10.1093/brain/awab385
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeEngland
dcterms.dateAccepted2021-09-28
dc.rights.embargodate2022-3-5
dc.identifier.eissn1460-2156
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1093/brain/awab385
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-10-08
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV